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Abstract
C. trachomatis infection of the genital tract is the most common sexually transmitted infection and
has a worldwide distribution. The consequences of infection have an adverse effect on the
reproductive health of women and are a common cause of infertility. Recent evidence also
suggests an adverse effect on male reproduction. There is a need to standardise the approach to
managing the impact of C. trachomatis infection on reproductive health. We have surveyed current
UK practice towards screening and management of Chlamydia infections in the fertility setting.
We found that at least 90% of clinicians surveyed offered screening. The literature on this topic
was examined and revealed a paucity of solid evidence for estimating the risks of long-term
reproductive sequelae following lower genital tract infection with C. trachomatis. The mechanism
for the damage that occurs following Chlamydial infections is uncertain. However,
instrumentation of the uterus in women with C. trachomatis infection is associated with a high risk
of pelvic inflammatory disease, which can be prevented by appropriate antibiotic treatment
andmay prevent infected women from being at increased risk of the adverse sequelae such as
ectopic pregnancy and tubal factor infertility. Recommendations for practice have been proposed
and the need for further studies identified.
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Introduction
C. trachomatis, an obligate intracellular bacterium, is one of the most common sexually
transmitted infections with 89 million new cases thought to occur globally per
annum(Adams et al., 2004; Manavi, 2006; Bébéar & de Barbeyrac, 2009). In Europe, the
reported incidence of Chlamydial infections has increased in the past ten years, some of
whichmay be accounted for through increased testing and the availability of more sensitive
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tests, but may also reflect an increase in risk-taking behaviour. In 2006, there were 112,473
C. trachomatis diagnoses identified from laboratory reports in England and Wales and
17,962 from Scotland (Health Protection Agency, 2007).
C. trachomatis infection is =common in those under 25 yrs, with rates decreasing thereafter
(Holmes et al., 1999; Horner and Boag, 2006). One in 14 young people (<25yrs old)
screened outside departments of Genitourinary Medicine as part of the National Chlamydia
Screening Programme in England were Chlamydia-positive (National Chlamydia Screening
Programme, 2009). This probably represents selective testing of higher risk individuals as
population based studies have observed prevalences in the range 2-6% with a higher
prevalence in women aged 16-19 and men 20-24 (Fenton et al., 2001; Macleod et al., 2005).
There are some studies of C. trachomatis in men and women undergoing investigations for
infertility using modern screening methods. The C. trachomatis positivity rate is about 2-5 %
in men and women and may be as low as 1% or as high as 13% among couples (Bezold et
al., 2007; Eggert-Kruse et al., 1997; Idahl et al., 2004; Imudia et al., 2008; Samra et al.,
1994) as only one partner of a couple may test positive (Clad et al., 2001; Idahl et al., 2004).
Current infection does not necessarily mean recent infection, as the infection can persist for
many years in the absence of treatment (Molano et al., 2005). The major sequelae of C.
trachomatis infection in women are tubal factor infertility and tubal ectopic pregnancy.
Sequelae of C. trachomatis infection in men may include male factor infertility but why this
occurs remains uncertain (Joki-Korpela et al., 2009).
Annual NHS costs due to C. trachomatis infection and its purported complications are
estimated at above £100 million (Department of Health, 2004). In 2007, due to concern
about the public health impact of C. trachomatis infection, the National Chlamydia
Screening Programme (National Chlamydia Screening Programme, 2009) was introduced in
England offering screening to anyone under 25 (http://www.Chlamydiascreening.nhs.uk).
However, in Scotland no such programme has been introduced. The Scottish Intercollegiate
Guidelines Network (2009) state that ‘in the absence of a complication rate of 10% or more
in women with untreated Chlamydial infection, there is no evidence that a screening
programme is cost effective with regard to reducing morbidity’. Furthermore, the National
Collaborating Centre for Women’s and Children’s Health (2008) recommended that
chlamydia screening should not be offered to pregnant women, based on the evidence
supporting the NICE Routine Antenatal Care Guideline.
With regard to infertility patients receiving treatments such as IVF, the Royal College of
Gynaecologists (1998) recommended that women should be screened for C. trachomatis, or
given appropriate antibiotic prophylaxis, before any uterine instrumentation takes place.
This was reiterated in the later NICE guidelines (National Collaborating Centre for
Women’s and Children’s Health, 2004). However, Sowerby and Parsons (2004) noted that
53% of UK clinics either screen the female partner or give appropriate antibiotic
prophylaxis. In the recruitment of sperm, egg and embryo donors the most recent UK
guidelines produced by the Association of Biomedical Andrologists, Association of Clinical
Embryologists, British Andrology Society, British Fertility Society and Royal College of
Obstetricians Gynaecologists (2008) recommend that all donors be screened for C.
trachomatis prior to donation, and this is reiterated in the 8th Edition of the HFEA Code of
Practice (HFEA, 2009).
Aims
1. To survey current practice in relation to C. trachomatis screening and treatment
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2. To produce evidence-based guidelines to help UK fertility clinics in their practice
of screening and managing couples with possible C. trachomatis infection.
Materials and methods
A questionnaire was developed examining key questions relating to the practice of
chlamydia screening and management. The questionnaire was sent to the Person
Responsible in all HFEA Licensed Clinics and to all practicing consultant gynaecologists
registered with the Royal College of Obstetricians and Gynaecologists. There were separate
questionnaires for private and NHS services. Where both NHS and private patients were
treated they were requested to fill in both questionnaires in order to distinguish any
differences.
Questions were asked in relation to whether patients were offered screening, the type of
screening offered (e.g. swabs, serology), type of treatment given if positive. Statistical
analysis was undertaken using the Chi square test.
Results
A total of 1253 questionnaire were sent out; a follow up request was not sent to those that
did not respond. In total 220 responses were received giving a16% response rate, Table 1
summarises the main findings. Of the responses received, 91 stated that they provide private
services and 181, NHS services. Of the centres that responded to the question on why they
undertook serology, 16 of 72 (22.2%) indicated they did so to assess the risk of current
infection (data not shown). Less than 18% of the centres surveyed used Chlamydia serology
routinely and most centres did not use it selectively either. Over 70% of centres were not
sure which assay was used to test for chlamydial antibodies (Table 1).
Discussion of survey findings
As only 16% of individuals surveyed responded we are limited in our ability to assert that
the findings are representative of practice in the UK. Nonetheless, the results suggest that
the majority of patients are screened for C. trachomatis though many centres apply a
selective approach and do not screen all patients. Thus, it is plausible that most centres are
currently compliant with the NICE recommendations; in contrast to a survey undertaken 5
years ago (Sowerby & Parson 2004). It is notable that of those not offering screening, it was
higher in the private sector though not statistically significantly so. It may be that these were
patients undergoing specific treatment such as IVF or they may previously have been
investigated in an NHS setting. It is however, not possible to be certain as to why s this
question was not asked.
It is significant that several centres were uncertain which serological assay was used because
interpretation of serology results is dependent on the test used. Furthermore, the finding of
serology being used for assessing current infection in a fifth of centres that did the test,
suggests that it is often used for the wrong reasons. This indicates further training is required
by many centres in the use of Chlamydia serology.
Scope
The remainder of this paper reviews the current literature systematically in order to provide
evidence based guidance in the following areas:
□ C. trachomatis infection and adverse reproductive outcome
□ Screening for C. trachomatis in infertile women
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□ Screening for tubal damage using chlamydial antibody testing (serology).
□ Male infertility and C. trachomatis
□ Diagnosis and detection of chlamydial infection using Nucleic Acid
Amplification Tests.
□ Detection of current chlamydial infection using serology
□ Treatment of patients diagnosed with chlamydial infection
□ Prophylactic antibiotic use
□ Counselling and guidance in the event of a positive result.
□ Contact tracing for patients recognised as having current infection
□ Counselling in the infertility setting
□ Mode of obtaining result of chlamydia screening
□ Storage of gametes and embryos
C. trachomatis infection and adverse reproductive outcome
There is good evidence that many individuals infected with C. trachomatis become micro-
organism detection negative with time (Quine et al., 1996; Molano et al., 2005). Women
usually present many years after they were at greatest risk of having an infective episode.
Thus tests which only detect the presence of the micro-organism, such as nucleic acid
amplification tests (NAATs) cannot be used to assess previous exposure to C. trachomatis.
Serology, a measure of past exposure to chlamydial infection, has been measured in case
control studies of women with infertility (Land et al., 1998). Its usefulness lies in being able
to detect women who have previously been exposed to chlamydia infection,and identified as
being at high risk of tubal damage (Akande, 2002). However, studies adopting this approach
have been criticised because of poor assay sensitivity and specificity, there having been no
rigorous evaluation against large numbers of well-defined antibody positive and negative
control sera.
In the absence of treatment, women infected with C. trachomatis may develop pelvic
inflammatory disease (PID) which can result in tubal factor infertility (TFI), ectopic
pregnancy (EP) and chronic pelvic pain (Westrom et al., 1992; Paavonen & Eggert-Kruse,
1999; Hu et al., 2004; Simms & Horner, 2008). However, this familiar phrase in the world
of chlamydial research belies a fundamental problem; uncertainty about how many cases of
genital C. trachomatis infection go on to develop PID and its associated sequelae (Wallace et
al., 2008).
Instrumentation of the uterus in women with C. trachomatis infection is associated with a
high risk (>50%) of developing pelvic inflammatory disease following termination of
pregnancy (Blackwell et al., 1993). A trial comparing screening of C. trachomatis versus
non screening, prior to termination of pregnancy demonstrated a significant reduction in post
abortion pelvic inflammatory disease at 4 weeks in those screened and treated if positive
(Giertz et al., 1987). There is also strong evidence to suggest that women with confirmed
pelvic inflammatory disease are at increased risk of ectopic pregnancy, tubal factor
infertility and chronic pelvic pain (Weström et al., 1992).
Difficulties in determining the effect of female genital C. trachomatis infection on adverse
reproductive outcome stem from not only the design of the studies, but from the lack of a
reliable method for measuring a history of PID. Much of the current assumptions on risk of
subsequent infertility are based on retrospective case-control studies (Walters et al., 1988;
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Chrysostomou et al., 1992; Weström et al., 1992; Odland et al., 1993; Van Valkengoed et
al., 2004; Low et al., 2006; Bakken et al., 2007; Bjartling et al., 2007; and Machado et al.,
2007). Many of these studies have been performed on populations where infertility was at
the extremes of the distribution i.e., extremely common or rare, or used data that did not
account for misdiagnoses, and there is considerable error in their estimates of risk ratios
(Van Valkengoed et al., 2004; Bakken, 2008; Garnett, 2008). Moreover, retrospective and
prospective case control studies on infertility are prone to confounding variables that have
not always been accounted for, such as the effect of other sexually transmitted infections
(e.g. Neisseria gonorrhoea and syphilis).
The mechanism by which C. trachomatis infection accounts for adhesions, tubal damage or
occlusion in humans, leading to female infertility is unclear. It is believed to be primarily
immunologically mediated and not a direct consequence of destruction of tissue by the
organism (Rice & Schacter, 1991; Beatty et al., 1994), although more recent evidence does
support a direct cytotoxic effect of C. trachomatis on the ciliated epithelium (Baczynska et
al., 2007). There are experimental animal models (mainly in rodent species) of genital
Chlamydial infection that provide clues to disease pathogenesis. However, these
experimental infections are usually conducted using defined infectious doses under highly
controlled conditions for relatively short periods in animals that have limited genetic
variability and different immune evasion strategies than in man (Brunham & Rey-Ladino,
2005). Consequently, care needs to be taken when interpreting the data for the pathogenesis
of human Chlamydial infections where all of the above factors vary greatly. It is thought that
lower genital tract C. trachomatis infection ascends to the upper reproductive tract resulting
in salpingitis, and it has been proposed that an antibody response to the Chlamydial heat
shock protein (hsp-60) may cause a tubal inflammatory response leading to tubal blockage
or a predisposition to tubal implantation (Ault et al., 1998; Bjartling et al., 2007). Repeated
infections with C. trachomatis are also thought to increase tubal damage (Hillis et al., 1997;
Westrom et al.,1992; Rank et al., 1995).
Recommendation—There is an association between C. trachomatis infection and adverse
reproductive sequelae in women; efforts should therefore be made to prevent infection.
Screening for C. trachomatis in infertile women
Due to the silent nature of C. trachomatis infection, most infected women are asymptomatic
and therefore go unrecognised and untreated. Although the prevalence of C. trachomatis
among subfertile women in the UK is only 1.9% (MacMillan & Templeton 1999), uterine
instrumentation carried out routinely as part of the infertility investigation may reactivate or
introduce upper tract dissemination of endocervical C. trachomatis infection, resulting in
iatrogenic pelvic inflammatory disease. Clinical pelvic infection following
hysterosalpingography (HSG) has been reported in up to 4% of cases and in 10% of patients
with tubal disease (Forsey et al., 1990). Prophylactic antibiotics are effective in reducing this
condition and should be considered (National Collaborating Centre for Women’s &
Children’s Health, 2004). There is evidence that screening for, and treating cervical C.
trachomatis can reduce the incidence of pelvic inflammatory disease in women at increased
risk of this infection. The Chief Medical Officer’s Expert Advisory Group on Chlamydia has
called for action to reduce the prevalence and morbidity of Chlamydial infection. It
recommends that consideration be given to screening couples attending fertility clinics and
women undergoing procedures requiring instrumentation of the uterus.
Recommendation—Before undergoing uterine instrumentation women should be offered
screening for C. trachomatis. Prophylactic antibiotics should be considered before uterine
instrumentation if screening has not been carried out.
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Screening for tubal damage using Chlamydia antibody testing (serology)
Laparoscopy is currently recognised as the gold standard for diagnosing tubal infertility,
though other methods such as Hystero Contrast Sonography and Hysterosalpingograpy exist.
Infection with C. trachomatis results in the formation of antibodies detectable in the serum.
Studies using laparoscopy confirm that serological evidence of past infection with C.
trachomatis is associated with a significantly increased risk of women suffering tubal
infertility (Akande et al., 2003; Coppus et al., 2007). Furthermore, the severity of tubal
damage found in infertile women is directly related to serum antibody titre levels (Akande,
2003).
Because there are justified constraints to the indiscriminate use of laparoscopy and other
invasive diagnostic tests, there is a need to minimise the number of patients who do not have
tubal damage who are subjected to these investigations. Screening is defined as a procedure
that helps identify a specified disease or condition (in this context tubal damage). Most
screened individuals will be unaffected. A meta-analysis (Mol et al., 1997) showed that the
performance of Chlamydia antibody testing on detecting tubal damage depended on the
assay used, and found the WIF test with the ELISA and MIF test to be superior to the
immuno-peroxidase assay.
Clinical judgment and not a statistical calculation are often required to decide what test to
use. For example in screening for lethal disease (e.g. HIV), high sensitivity is desirable
though the trade off is usually lower specificity. However, when dealing with a non life-
threatening condition such as tubal damage, a high cut off (lower sensitivity) may be chosen
which may miss some cases but lead to fewer women who do not have the disease being
subjected to invasive and costly laparoscopy (high specificity).
Recommendation—Serology is non-invasive and may be used as a screening test to
detect evidence of past chlamydial infection. This may help identify women at high risk of
having tubal damage as a cause of their infertility.
Male infertility and C. trachomatis
There have been a number of studies on the relationship between C. trachomatis infection
and sperm quality, with conflicting results. However, as for the studies in women (above),
there have been major differences in study design with: (a) significant variation in the
methodology used to measuring the history of chlamydial infection (i.e. serology versus
molecular methods); as well as (b) variable and sometimes inadequate methods to assess
semen quality (see Pacey and Eley, 2004 for review). More recent studies (Hosseinzadeh et
al., 2004; Bezold et al., 2007; Al-Mously et al., 2009), using molecular methods to detect
infection, and robust methods of laboratory andrology to examine semen, have generally
found that men with a current infection of C. trachomatis have poorer quality ejaculates
compared than men who do not. It is unclear whether this is because of reduced levels of
spermatogenesis in the presence of the bacterium, or whether infection causes an altered
ejaculatory response. However, it has been observed that persistent infection can result in
the scarring of ejaculatory ducts or loss of stereocilia (Gonzalez-Jiminez & Villanueva-
Dmaz, 2006).
In addition to any changes in semen quality, there is growing evidence to suggest that
exposure to C. trachomatis can affect sperm function (Pacey and Eley, 2004; Eley et al.,
2005b). In vitro experiments have shown that C. trachomatis triggers tyrosine
phosphorylation of sperm proteins (Hosseinzadeh et al., 2000), induces premature sperm
death (Hosseinzadeh et al., 2001) and stimulates an apoptosis-like response in sperm (Eley
et al., 2005a; Satta et al., 2006), leading to increased levels of sperm DNA fragmentation
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(Satta et al., 2006; Gallegos et al., 2008). At least some of these effects are caused by
lipopolysaccharides. (Hosseinzadeh et al., 2003).
Recommendation—Some evidence indicates that C. trachomatis infection can affect
sperm quality and sperm function. However it has not been shown that empirical treatment
improves reproductive outcome in males.
Diagnosis and detection of C. trachomatis infection using Nucleic Acid Amplification Tests
NAATs are now the test of choice for detecting current C. trachomatis infection (Horner &
Boag, 2006). These tests have a high sensitivity (>90%) and specificity (>99.5%) for
detecting the micro-organism. Although no single test provides 100% sensitivity and
specificity, NAATs are the most accurate tests on the market. Four commercial assays are
currently available for routine use and it is anticipated that this number will increase.
However, it can be demonstrated in vitro that C. trachomatis can enter a latent state under
stressful conditions such as exposure to interferon gamma (IFN-γ) (an important cytokine
involved in cell mediated immunity), exposure to penicillins (Hogan et al., 2004) or amino
acid starvation. This state allows C. trachomatis to remain dormant but, on removing the
stressful conditions, the bacteria can subsequently be recovered from culture. This may be
an adaptive survival mechanism in vivo (Hogan et al., 2004) and it has been proposed that
women with tubal disease who are Chlamydia-antibody positive, in particular with the IgA
antibody, are at risk of having persistent latent infection (Patton et al., 1994; Witkin &
Linhares, 2002).
In men a first voided urine specimen is the test of choice and is just as accurate as a urethral
swab, which can be painful. In women although a cervical specimen is to be preferred there
is increasing evidence that a vulvo-vaginal specimen is just as accurate (Horner & Boag,
2006). Although first voided urine specimens are licensed in women, studies indicate a wide
variation in sensitivity suggesting it may not be as reliable in some hands (Horner & Boag,
2006). This probably reflects the lower Chlamydial load in this specimen type compared to
cervical and vulvo-vaginal specimens (Michel, 2007; Wiggins, 2009).
It is important that care is taken, and local guidelines are followed, when obtaining and
transporting these specimens, as poor quality specimens may result in reduced sensitivity.
To avoid contamination (Horner & Boag, 2006) men and women should have held their
urine for 2 hours (minimum one hour) and when taking a vulvo-vaginal or cervical swab it
should be rotated for at least 15 seconds.
Recommendation—Although no single test provides 100% sensitivity and specificity,
NAATs are the most accurate tests on the market. For women this should either be a cervical
or vulvo-vaginal specimen.
Detection of current Chlamydial infection using serology
Serology assays to detect C. trachomatis antibodies in exposed patients are liable to cross-
reaction with sera from patients exposed to other chlamydial species, particularly C.
pneumoniae (Johnson & Horner, 2008), a common respiratory pathogen with which it shares
genetic homology (Kalman et al., (1999). Chlamydial antigens, such as the 60kDa heat
shock protein (hsp60) and lipopolysaccharide, cross-react with other bacterial species
(Newhall et al., 1982; Kalman et al., 1999; Sanchez-Campillo et al., 1999). The
microimmunofluorescence (MIF) assay, which detects antibodies to Chlamydial elementary
bodies, has long been considered to be the ‘gold standard’ for serodiagnosis of C.
trachomatis (Persson, 2002; Johnson & Horner, 2008). However, the procedure lacks
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standardisation, is subjective, not designed for high-throughput use and its specificity is
compromised by cross-reactivity with other Chlamydial species (Persson, 2002; Johnson &
Horner, 2008). The highly immunogenic major outer membrane protein (MOMP) making up
60% of the total outer membrane protein (Caldwell et al., 1981), is the basis of several
commercially produced ELISAs using C. trachomatis specific peptides (Johnson & Horner,
2008). However, although specificity is high; >95% in women, sensitivity is <60% and that
in men, lower still ~40% (Wills et al., 2009). There is currently no evidence supporting the
use of Chlamydial serology for detecting persistent hidden (NAAT negative) infection
which may be at risk of reactivating (Dietrich et al., 2008). A positive chlamydial serology
test should be viewed with caution in attributing causality because of problems with
sensitivity and specificity.
Recommendation—Chlamydial antibody testing (serology) is not useful in detecting
current infection.
Treatment of patients diagnosed with C. trachomatis infection
Azithromycin 1g and doxycycline 100mgs bd for 7 days have been shown to be >95%
effective in the treatment of uncomplicated lower genital tract C. trachomatis infection.
(Horner and Boag, 2006; Horner, 2008). For those with upper genital tract disease i.e.,
pelvic inflammatory disease, a prolonged course of treatment for up to 14 days is
recommended (Royal College of Obstetricians and Gynaecologists, 2008).
Recommendation—C. trachomatis detection-positive patients should be assessed for the
presence of upper genital tract disease and if present treated according to RCOG guidelines.
Patients with uncomplicated disease should be treated with: Azithromycin 1g or
Doxycycline 100mgs bd for seven days.
Prophylactic antibiotic use
There is no evidence to support the use of prophylactic antibiotics in women who are
NAAT-negative and chlamydia-antibody positive. However further studies are merited as
the potential for persistent infection in antibody-positive women in the presence of a
negative lower genital tract NAAT cannot definitely be excluded as the evidence is
inconsistent. A randomised controlled trial of prophylactic antibiotics in Chlamydia-
antibody women (using new C. trachomatis specific MOMP peptide assays) who are NAAT
negative is required.
Recommendation—Those women who are NAAT-positive for C. trachomatis or are
contacts of partners who are C. trachomatis NAAT-positive should be treated.
Counselling and guidance in the event of a positive test result
C. trachomatis infection remains a stigma for many and testing can be a sensitive issue. This
section highlights the patient’s need for information, the importance of support for patients
receiving a positive result and the need for guidance in providing advice (Table 2). Whilst
general practitioners undertake the vast majority of screening for sexually transmitted
diseases (STIs) (Temple-Smith et al., 1999; McNulty et al., 2004), specialist (tertiary)
services have a valuable role in meeting these needs In some cases, patients may seek a
private referral.
It should also be remembered that C. trachomatis infection can persist for years in some
individuals (Molano et al., 2005) while their regular partner may not test positive (Quinn et
al., 1996; Clad et al., 2001). Thus the detection of C. trachomatis does not necessarily mean
recent acquisition from another partner. Table 2 provides a framework for counselling a
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patient who is found to be positive for C. trachomatis based on the Bristish Association for
Sexual Health and HIV guidelines.
Recommendation—Health professionals offering Chlamydia screening should be trained
to inform individuals of the potential effects of positive screening.
Contact tracing for patients recognised as having current infection
Partner notification for sexually transmitted infections such as C. trachomatis is essential to
prevent re-infection of the patient, sequelae in untreated partners and onward transmission.
Patients diagnosed with C. trachomatis should be advised to inform partners at risk and/or be
referred to Genitourinary Medicine (GUM) for management and support, with partner
notification. This can be undertaken successfully outside GUM departments by nurses with
minimal training and on-going support from a health adviser (Low et al., 2006; Horner &
Boag, 2006). Health advisers usually work in GUM departments and specialise in partner
notification.
National guidelines recommend that all sexual contacts within the past six months should be
offered treatment and anti-Chlamydial therapy (Horner & Boag, 2006). Partners should not
be directly informed by the service without the consent of the patient who has tested
positive.
Partners may be managed by the Infertility Clinic, or referred to GUM where treatment is
free and confidential. Some partners may prefer to attend their GP. Partners should be
offered testing and treatment without delay, to reduce the risk of patient re-infection.
Treatment of partners should be given on the day the test is taken, without waiting for the
result. Partners who have recently tested negative should still be offered treatment.
Patients who are unwilling to notify their partners themselves should be referred to a GUM
clinic for assistance from a Health Adviser who will inform the partner confidentially,
without mentioning the patient’s name. Patients who test negative but report a history of
treatment for C. trachomatis during their current relationship should be asked to confirm that
their partner was treated at the same time.
Recommendation—Partner notification following C. trachomatis infection is advisable to
prevent re-infection of the patient, sequelae in untreated partners and onward transmission.
Counselling in the infertility setting
The main focus of counselling in this setting is to inform the patient of the association of a
positive Chlamydial result with tubal infertility and ectopic pregnancy. Patients need to be
comfortable and informed before consenting to screening; accurate information which can
normalise and subsequently de-stigmatise infection must be available; and feelings of
embarrassment should be addressed in a sympathetic manner. The very real concerns that
exist for patients regarding stigma, informing partners, confidentiality, physically being
screened, and, in particular, future reproductive health, make a positive diagnosis more
difficult to cope with.
Screening for C. trachomatis often evokes anxiety through the realisation that there is a
possibility of being infected. In one study, the verbal and written information provided to
patients led to most recalling the possibility of infertility after infection (Duncan et al., ;
2001). This provoked a mixed reaction; relief that infection was diagnosed but anxiety about
future reproductive morbidity.
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Recommendation—Patients should be informed of the potential association between C.
trachomatis infection and adverse reproductive outcome.
Mode of obtaining result of C. trachomatis screening
Waiting for the result of screening causes concern about the implications of a potential
positive diagnosis and collecting the result in itself can be the cause of much anxiety. The
method of obtaining the result is important, as some methods will be seen as risking
confidentiality, unsupportive or potentially increasing anxiety (Dixon-Woods et al., 2001).
Some patients prefer to be in control by being able to telephone for their results, whilst
others will prefer a second appointment, to allow time to absorb the information and ask
questions; others may prefer to receive the result by post. It is recommended that units
develop adequate policies for providing some or all of these options.
Recommendation—Patients should be offered the opportunity to choose how they
receive the result of their Chlamydia test.
Storage of gametes and embryos
Since it is known C. trachomatis can survive in liquid nitrogen (Sherman & Jordan, 1985)
and that infection following insemination with cryopreserved donor semen is possible
(Broder et al., 2007), the freezing and storage of gametes and embryos from patients with an
active C. trachomatis infection is of obvious concern. This is not only to prevent women
who receive treatment with thawed gametes and embryos from becoming infected with C.
trachomatis, but because of the theoretical concern that the bacteria may cross-contaminate
other (C. trachomatis negative) samples being stored in the same cryostorage vessel.
To date, such cross contamination has only been shown with regard to Hepatitis B during
storage of peripheral blood stem cells (Tedder et al., 1995) and has never been demonstrated
during reproductive tissue storage. However, the HFEA now require that all patients placing
material in storage be screened for bloodborne viruses prior to placing material in storage
(Human Fertilisation and Embryology Authority, 2009). For patients undergoing planned
IVF treatment, a similar level of risk reduction will be achieved if both partners are screened
and treated for C. trachomatis.
Recommendation—All patients should be screened for C. trachomatis prior to placing
gametes or embryos in storage. Where embryos are created, the gamete providers should be
screened, and if positive treated.
However, this may not be possible for men banking sperm prior to cancer therapy, as there
is often insufficient time between diagnosis and the start of treatment to allow C.
trachomatis testing and treatment (Tomlinson and Pacey, 2003). In such cases, men who are
C. trachomatis positive should be advised at the time of storage about the risks to future
partners of acquiring an infection and this should be reiterated at the time of any future
treatment.
Recommendation—Where screening is not possible, the gamete provider and their
partner should be told of the risks of infection of using unscreened material in treatment.
The risk of C. trachomatis negative samples being contaminated with bacteria from positive
(unscreened material) will vary according to the type of storage systems used (see
Tomlinson, 2009). Whilst sperm washing before freezing could theoretically help to reduce
the bacterial load in C. trachomatis positive samples, this remains unproven and
Akande et al. Page 10
Hum Fertil (Camb). Author manuscript; available in PMC 2011 April 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
experimental data suggest that sperm washing is only partially effective in removing the
bacteria from men with an active infection (Al-Mously et al., 2009).
Recommendation—Laboratory staff should carry out a risk assessment of their storage
system to reduce the likelihood of cross-contamination with Chlamydia during storage.
Conclusion
There is a paucity of solid evidence for estimating the risks of long-term reproductive
sequelae following lower genital tract infection with C. trachomatis. Nevertheless
instrumentation of the uterus in women with C. trachomatis is associated with a high risk of
pelvic inflammatory disease, which can be prevented by treatment. There is good evidence
that women with pelvic inflammatory disease are at increased risk of ectopic pregnancy and
tubal factor infertility.
There is a need for:
1. Well-designed prospective female and male patient cohort studies on clearly
defined adverse reproductive outcomes, such as tubal ectopic pregnancy and semen
quality. Quantifying risk is fundamentally important as women and men diagnosed
with apparently uncomplicated C. trachomatis infection need to be given reliable ,
evidence-based information on their subsequent risk of infertility.
2. Randomised controlled treatment trials of chlamydia antibody-positive NAAT
negative women undergoing investigation for infertility.
3. Randomised controlled trials to investigate whether semen quality and sperm
function is improved following empirical treatment for C. trachomatis.
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Table 1
Findings of survey in relation to clinic
practice for private and NHS patients
NHS (n=181)
Private (n=91)
Screening offered
in clinic
82 (90.1%) 174 (96.2%) NS
Screening offered to all
patients
47 (51.6%) 97 (53.6%)
Genital swab
used as screening
method
75 (82.4%) 151 (83.4%) NS
Type of treatment used if positive
Doxyxlycline 85 (47.0%) 42 (46.2%) NS
Azithromycin 72 (39.8%) 35 (38.5%) NS
Serology always
used
16 (17.6%) 25 (13.8%) NS
Never used 61 (67.0%) 122 (67.4%) NS
Not sure of what
type of serology
66 (72.5%) 136 (75.1%) NS
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Table 2
The following may be used as guidance for counselling a patient with Chlamydia infection
1. What is C.trachomatis and how it is transmitted
a. It is a common infection in sexually active individuals
b. It is primarily sexually transmitted, but may not be always so
c. If asymptomatic there is evidence that it could have persisted for months or years
2. The diagnosis of C.trachomatis:
a. It is often asymptomatic in both men and women
b. Whilst tests are accurate, no test is absolutely so
3. The complications of untreated C.trachomatis
4. Side effects and importance of complying fully with treatment and what to do if a
dose is missed.
5. The importance of their sexual partner(s) being evaluated and treated.
6. Advised to abstain from sexual intercourse until they and their partner(s) have
completed therapy (and waited seven days if treated with azithromycin).
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